Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in ...

Lilly said in a statement that patients could buy the Zepbound vials for $499 per month on its LillyDirect website, roughly 23% cheaper than the $650 it charges for its injector pen to insured ...